论文部分内容阅读
目的探讨多药耐药基因1(MDR1)、谷胱甘肽S转移酶(GST-)、拓扑异构酶Ⅱ(TOPⅡ)和多药耐药相关蛋白(MRP)在鼻咽癌组织中的表达及其临床意义。方法采用免疫组化法检测45例鼻咽癌患者化放疗前鼻咽癌组织MDR1、GST-、TOPⅡ和MRP蛋白表达。T3~4 N2~3期和T2N1期患者鼻咽癌患者采用同期化疗,其中T3~4 N2~3期鼻咽癌患者采用新辅助化疗,化疗结束后7~14 d放疗。化放疗结束后6个月进行评价。结果 GST-、TOPⅡ和MRP蛋白表达与鼻咽癌病理类型无关(P=0.933,0.360,0.944),而MDR1表达与病理类型有关(P=0.037);MDR1、GST-、TOPⅡ和MRP蛋白表达与临床分期和近期疗效均不相关(均P>0.05)。结论 MDR1、GST-、TOPⅡ和MRP表达对鼻咽癌临床分期和近期疗效无意义。
Objective To investigate the expression of multidrug resistance-1 (MDR1), glutathione S-transferase (GST-), topoisomerase Ⅱ (TOPⅡ) and multidrug resistance-associated protein (MRP) in nasopharyngeal carcinoma And its clinical significance. Methods Immunohistochemistry was used to detect the protein expressions of MDR1, GST-, TOPⅡ and MRP in 45 patients with nasopharyngeal carcinoma before radiotherapy. Patients with nasopharyngeal carcinoma of stage T3 ~ 4, stage N2 ~ 3, and stage T2N1 were treated with concurrent chemotherapy, of which neoadjuvant chemotherapy was performed in patients with stage N2 ~ 3 of N2 ~ 3 and radiotherapy 7 ~ 14 days after the end of chemotherapy. Chemotherapy after 6 months to evaluate. Results The expressions of GST-, TOPⅡ and MRP proteins were not associated with the pathological types of NPC (P = 0.933,0.360,0.944), but the expression of MDR1 was correlated with pathological types (P = 0.037). The expressions of MDR1, GST-, Clinical stage and recent efficacy are not related (all P> 0.05). Conclusion The expressions of MDR1, GST-, TOPⅡ and MRP are not significant for the clinical stage and short-term curative effect of NPC.